Influence chronopharmacology therapy methionine (melaxen) on the dynamics of sleep disturbance, cognitive and emotional disorders, brain-derived neurotrophic factor (BDNF) in patients with cerebral stroke in the early and late recovery periods

Костенко, Е. В.

doi:10.17116/jnevro20171173156-64

Cited by 4 publications

(3 citation statements)

References 25 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We retrieved 95 articles for full-text screening, from which 29 studies were excluded for the following reasons: animal sample size, review article, duplicated articles from one same study, in vitro study, and reporting one single measure in one single study group at only one-time point. An additional number of 5 articles were removed during the data extraction because of: insufficient data despite author contact [ 22 , 26 ], reporting BNGF instead of BDNF [ 23 ], unclear data from an extensive cohort study (Framingham [ 3 ]), reporting peripheral BDNF in association with another biomarker instead of pure measures [ 27 ].…”

Section: Resultsmentioning

confidence: 99%

Circulating brain-derived neurotrophic factor as a potential biomarker in stroke: a systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

Background Stroke, an acute cerebrovascular event, is a leading cause of disability, placing a significant psycho-socioeconomic burden worldwide. The adaptation and reorganization process following any neuronal damage is regarded as neuroplasticity. Among many factors believed to attribute to this process, Brain-derived Neurotrophic Factor (BDNF) is a neurotrophin coordinating neuroplasticity after various neurological disorders such as stroke. Methods We conducted a systematic search in the main electronic medical databases in January 2021. Primarily we want to compare BDNF levels between patients with stroke and healthy controls (HC). Additional aims included investigation of (1) longitudinal changes in the BDNF levels post-stroke, (2) effects of physical training, (3) repeated transcranial magnetic stimulation (rTMS), and presence of depression on BDNF levels in patients with stroke. Results Among 6243 reviewed records from PubMed, Web of Science, and Scopus, 62 studies were eligible for inclusion in our systematic review. Subjects with stroke, n = 1856, showed lower BDNF levels compared to HC, n = 1191 (SMD [95%CI] = − 1.04 [− 1.49 to − 0.58]). No significant difference was detected in the level of BDNF through time points past stroke. BDNF levels were lower in the patients with depression compared to non-depressed subjects (SMD [95%CI] = − 0.60 [− 1.10 to − 0.10]). Physical training had an immediate positive effect on the BDNF levels and not statistically significant effect in the long term; SMD [95%CI] = 0.49 [0.09 to 0.88]) and SMD [95%CI] = 0.02 [− 0.43 to 0.47]). Lastly, rTMS showed no effect on the level of BDNF with 0.00 SMD. Conclusions Our study confirms that stroke significantly decreases the level of BDNF in various domains such as cognition, affect, and motor function. As BDNF is the major representative of neuroplasticity within nervous system, it is believed that stroke has a significant impact on the CNS regeneration, which is permanent if left untreated. This effect is intensified with coexisting conditions such as depression which further decrease the BDNF level but the net impact yet needs to be discovered. We also conclude that exercise and some interventions such as different medications could effectively reverse the damage but further studies are crucial to reach the exact modality and dosage for their optimal effect.

show abstract

Section: Resultsmentioning

confidence: 99%

Circulating brain-derived neurotrophic factor as a potential biomarker in stroke: a systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…We retrieved 95 articles for full-text screening, from which 29 studies were excluded due to the following reasons: animal sample size, review article, duplicated articles from one same study, in vitro study, and reporting one single measure in one single study group. An additional number of 5 articles were removed during the data extraction because of insu cient data despite author contact (29,30), reporting BNGF instead of BDNF (31), unclear data from a big cohort study (Framingham (3)), reporting BDNF in association with other biomarker instead of pure measures (32). Finally, a total number of 62 articles were entered into our systematic review.…”

Section: Resultsmentioning

confidence: 99%

Circulating Brain-Derived Neurotrophic Factor as a potential biomarker in stroke: a Systematic review and Meta-analysis

Mojtabavi

Shaka²,

Momtazmanesh³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background Stroke, an acute cerebrovascular event, is a leading cause of disability, placing a significant psycho-socioeconomic burden worldwide. Neuroplasticity is adaptation and reorganization following neuronal damage. Brain-derived neurotrophic factor (BDNF) is a neurotrophin coordinating neuroplasticity after various neurological disorders such as stroke. Methods We conducted a systematic search in the main electronic medical databases through January 2021 and identified studies that measured blood levels of BDNF in patients with stroke. The primary aim was to compare BDNF levels between patients with stroke and healthy controls (HC). The secondary aims included investigation of (1) longitudinal changes in the BDNF levels post-stroke, (2) effects of physical training, (3) repeated transcranial magnetic stimulation (rTMS), and presence of depression on BDNF levels in patients with stroke. Results Among 6243 reviewed records from PubMed, Web of Science, and Scopus, 62 studies were eligible for inclusion. Subjects with stroke, n = 1856, showed lower BDNF levels compared to HC, n=1191 (SMD [95%CI] = -1.04 [-1.49 to -0.58]). No significant difference was detected in the level of BDNF through time points past stroke. BDNF levels were lower in the patients with depression compared to non-depressed subjects (SMD [95%CI] = -0.60 [-1.10 to -0.10]). Physical training had an immediate positive effect on the BDNF levels and not statistically significant effect in the long term; SMD [95%CI] = 0.49 [0.09 to 0.88]) and SMD [95%CI] = 0.02 [-0.43 to 0.47]). Lastly, rTMS showed no effect on the level of BDNF with 0.00 SMD. Conclusions This study confirms that stroke significantly affects the level of BDNF in various domains such as cognition, affect, and motor function. We believe that BDNF could be regarded as a valuable diagnostic biomarker for acute stroke and a potential prognostic biomarker for depression and cognitive deficits.

show abstract

“…In clinical settings, melatonin supplementation was associated with a lower risk of post-stroke delirium (a single dose of 2 mg/day at 20:00 within the first 24 h of ischemic stroke onset) compared to the control group [ 167 ] and with the shorter duration of mechanical ventilation and length of stay in the intensive care unit in a cohort of patients with hemorrhagic stroke (30 mg melatonin every night during a stay at the intensive care unit) [ 168 ]. In early and late rehabilitation periods, melatonin administration (3 mg daily for 3 months) led to an increase in the BDNF level that correlated with improved sleep, emotional status, and quality of life [ 169 , 170 ]. Regarding effects on functional outcomes, a pilot randomized study showed that 5-day treatment with melatonin in the acute phase of stroke led to a greater reduction in median NIHSS score, but not in mRS at a 3-month follow-up [ 171 ].…”

Section: Circadian System and Treatment Developments In Strokementioning

confidence: 99%

Circadian Factors in Stroke: A Clinician’s Perspective

Korostovtseva

Коломейчук

2023

Cardiol Ther

View full text Add to dashboard Cite

Stroke remains one of the leading causes of mortality and long-term and permanent disability worldwide despite technological innovations and developments in pharmacotherapy. In the last few decades, the growing data have evidenced the role of the circadian system in brain vulnerability to damage, the development and evolution of stroke, and short-term and long-term recovery. On the other hand, the stroke itself can affect the circadian system via direct injury of specific brain structures involved in circadian regulation (i.e., hypothalamus, retinohypothalamic tracts, etc.) and impairment of endogenous regulatory mechanisms, metabolic derangement, and a neurogenic inflammatory response in acute stroke. Moreover, the disruption of circadian rhythms can occur or exacerbate as a result of exogenous factors related to hospitalization itself, the conditions in the intensive care unit and the ward (light, noise, etc.), medication (sedatives and hypnotics), and loss of external factors entraining the circadian rhythms. In the acute phase of stroke, patients demonstrate abnormal circadian variations in circadian biomarkers (melatonin, cortisol), core body temperature, and rest–activity patterns. The approaches aimed at the restoration of disrupted circadian patterns include pharmacological (melatonin supplementation) and non-medication (bright light therapy, shifting feeding schedules, etc.) interventions; however, their effects on short- and long-term recovery after stroke are not well understood.

show abstract

Influence chronopharmacology therapy methionine (melaxen) on the dynamics of sleep disturbance, cognitive and emotional disorders, brain-derived neurotrophic factor (BDNF) in patients with cerebral stroke in the early and late recovery periods

Cited by 4 publications

References 25 publications

Circulating brain-derived neurotrophic factor as a potential biomarker in stroke: a systematic review and meta-analysis

Circulating brain-derived neurotrophic factor as a potential biomarker in stroke: a systematic review and meta-analysis

Circulating Brain-Derived Neurotrophic Factor as a potential biomarker in stroke: a Systematic review and Meta-analysis

Circadian Factors in Stroke: A Clinician’s Perspective

Contact Info

Product

Resources

About